NCT05670704View on ClinicalTrials.gov

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

August 8, 2024

Study Completion Date

August 8, 2024

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

ARGX-119

Patients receiving ARGX-119 IV or SC

OTHER

Placebo

Patients receiving Placebo IV or SC

Trial Locations (1)

9728

PRA Health Science, Groningen

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY

NCT05670704 - A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants | Biotech Hunter | Biotech Hunter